Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | IKBKB | O14920 | 2/20 | 0.54 |
| ▸ | KDM4E | B2RXH2 | 8/20 | 0.50 |
| ▸ | NPC1 | O15118 | 8/20 | 0.50 |
| ▸ | RAB9A | P51151 | 8/20 | 0.50 |
| ▸ | MAPT | P10636 | 7/20 | 0.50 |
| ▸ | PKM | P14618 | 1/20 | 0.50 |
| ▸ | ADCY1 | Q08828 | 2/20 | 0.48 |
| ▸ | MEN1 | O00255 | 6/20 | 0.45 |
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.45 |
| ▸ | KMT2A | Q03164 | 5/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 4/20 | 0.45 |
| ▸ | HPGD | P15428 | 3/20 | 0.45 |
| ▸ | GAA | P10253 | 3/20 | 0.45 |
| ▸ | STAT1 | P42224 | 1/20 | 0.45 |
| ▸ | NPSR1 | Q6W5P4 | 1/20 | 0.45 |
| ▸ | HSD17B10 | Q99714 | 4/20 | 0.44 |
| ▸ | USP2 | O75604 | 1/20 | 0.44 |
| ▸ | ESR1 | P03372 | 1/20 | 0.44 |
| ▸ | CASP1 | P29466 | 1/20 | 0.44 |
| ▸ | MAPK1 | P28482 | 4/20 | 0.44 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL3122330 | 0.89 | KDM4E (0.51) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3117979 | 0.84 | TARBP2 (0.58) | KDM4ENPC1RAB9AMAPTPKM | |
| SCHEMBL3759050 | 0.84 | IKBKB (0.74) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3127593 | 0.82 | IKBKB (0.67) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3117969 | 0.81 | IKBKB (0.61) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3124830 | 0.79 | IKBKB (0.67) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3129704 | 0.79 | IKBKB (0.72) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3117219 | 0.78 | IKBKB (0.66) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3129313 | 0.78 | IKBKB (0.50) | IKBKBKDM4ENPC1RAB9AMAPT | |
| SCHEMBL3127518 | 0.78 | IKBKB (0.55) | IKBKBKDM4ENPC1RAB9AMAPT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 27 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| EP-2170849-B1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LTD (GB) | 2016-12-21 | — | — | EP | disclosed |
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-9187465-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2015-11-17 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2015-02-26 | — | — | US | disclosed |
| US-8921544-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-8921544-B2 | Oxazole tyrosine kinase inhibitors | SAREUM LIMITED (GB) | 2014-12-30 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-8378095-B2 | Oxazole tyrosine kinase inhibitors | Saruem Limited (GB) | 2013-02-19 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2010-11-25 | — | — | US | disclosed |
| WO-2010055304-A2 | PHARMACEUTICAL COMPOUNDS | SAREUM LIMITED (GB) | 2010-05-20 | — | — | WO | disclosed |
| EP-2170849-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | Sareum Limited (GB) | 2010-04-07 | — | — | EP | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
| WO-2008139161-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | SAREUM LIMITED (GB) | 2008-11-20 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100298301-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | IKBKB 423/4885KDM4E 718/4885NPC1 3622/4885 |
| US-20150057282-A1 | OXAZOLE TYROSINE KINASE INHIBITORS | FLT3, AURKA, FLT1 | IKBKB 423/4885KDM4E 718/4885NPC1 3622/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.